AGP
Artia Global Partners Portfolio holdings
AUM
$389M
This Quarter Return
+2.9%
1 Year Return
+34.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$354M
AUM Growth
+$354M
(-9.3%)
Cap. Flow
-$32.3M
Cap. Flow
% of AUM
-9.13%
Top 10 Holdings %
Top 10 Hldgs %
80.31%
Holding
49
New
7
Increased
9
Reduced
4
Closed
5
Top Buys
| 1 |
Soleno Therapeutics
SLNO
|
$9.09M |
| 2 |
Novo Nordisk
NVO
|
$5.95M |
| 3 |
Viking Therapeutics
VKTX
|
$5.06M |
| 4 |
Revolution Medicines
RVMD
|
$4.35M |
| 5 |
Nuvalent
NUVL
|
$1.58M |
Top Sells
| 1 |
Merck
MRK
|
$54.8M |
| 2 |
Ocular Therapeutix
OCUL
|
$3.42M |
| 3 |
Apogee Therapeutics
APGE
|
$2.3M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
$2.04M |
| 5 |
Ionis Pharmaceuticals
IONS
|
$1.28M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Novo Nordisk
NVO
$251B
| $88.3M | 24.07% |
741,743
+50,000
| +7% | +$5.95M |
|
2
Eli Lilly
LLY
$657B
| $82M | 22.36% |
92,593
| – | – |
|
|
3
Viking Therapeutics
VKTX
$3.04B
| $33.7M | 9.2% |
532,879
+79,900
| +18% | +$5.06M |
|
|
ITCI
4
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $15.8M | 4.32% |
216,519
| – | – |
|
5
AstraZeneca
AZN
$248B
| $14.9M | 4.05% |
190,752
| – | – |
|
|
6
Soleno Therapeutics
SLNO
$3.6B
| $13.9M | 3.78% |
274,424
+180,000
| +191% | +$9.09M |
|
7
Alnylam Pharmaceuticals
ALNY
$58.5B
| $9.63M | 2.62% |
35,000
| – | – |
|
8
Vertex Pharmaceuticals
VRTX
$100B
| $8.79M | 2.4% |
18,900
| – | – |
|
9
Vaxcyte
PCVX
$4B
| $8.71M | 2.38% |
76,255
| – | – |
|
10
argenx
ARGX
$43.6B
| $8.21M | 2.24% |
15,138
| – | – |
|
11
Axsome Therapeutics
AXSM
$6.05B
| $7.89M | 2.15% |
87,848
| – | – |
|
12
Protagonist Therapeutics
PTGX
$3.67B
| $5.6M | 1.53% |
124,440
| – | – |
|
13
Neurocrine Biosciences
NBIX
$13.8B
| $5.18M | 1.41% |
45,000
| – | – |
|
|
14
Revolution Medicines
RVMD
$7.1B
| $4.35M | 1.19% |
+95,885
| New | +$4.35M |
|
15
Dyne Therapeutics
DYN
$1.92B
| $4.29M | 1.17% |
119,488
| – | – |
|
|
VRNA
16
Verona Pharma
VRNA
$9.16B
| $4.27M | 1.17% |
148,590
+17,800
| +14% | +$512K |
|
17
Merus
MRUS
$4.98B
| $4.01M | 1.09% |
80,171
+30,000
| +60% | +$1.5M |
|
18
Insmed
INSM
$28.8B
| $3.86M | 1.05% |
52,939
-497
| -0.9% | -$36.3K |
|
19
Celldex Therapeutics
CLDX
$1.47B
| $2.56M | 0.7% |
75,300
| – | – |
|
|
20
Crinetics Pharmaceuticals
CRNX
$2.92B
| $2.34M | 0.64% |
45,765
-40,000
| -47% | -$2.04M |
|
21
IDEAYA Biosciences
IDYA
$2.15B
| $2M | 0.54% |
62,992
+8,600
| +16% | +$272K |
|
|
MREO
22
Mereo BioPharma
MREO
$272M
| $1.73M | 0.47% |
421,359
| – | – |
|
|
SWTX
23
DELISTED
SpringWorks Therapeutics
SWTX
| $1.73M | 0.47% |
53,930
| – | – |
|
|
24
Nuvalent
NUVL
$5.52B
| $1.58M | 0.43% |
+15,437
| New | +$1.58M |
|
25
Xenon Pharmaceuticals
XENE
$2.98B
| $1.57M | 0.43% |
40,000
| – | – |
|